Join the Dexamethasone group to help and get support from people like you.
Dexamethasone News
Related terms: Dexamethasone Topical, Dexamethasone Ophthalmic, Dexamethasone Nasal, Dexamethasone Otic
High-Dose Glucocorticoids No Better Than Low-Dose for Sudden Hearing Loss
WEDNESDAY, Jan. 10, 2024 – For patients with idiopathic sudden sensorineural hearing loss (ISSNHL), systemic high-dose glucocorticoid therapy is no better than a lower-dose regimen, according to a...
Dexamethasone No Benefit in HIV-Positive With Tuberculous Meningitis
THURSDAY, Oct. 12, 2023 – For HIV-positive adults with tuberculous meningitis, adjunctive dexamethasone does not confer a benefit with respect to survival, according to a study published in the Oct....
FDA Medwatch Alert: FDA Warns Consumers Not to Purchase or Use Artri and Ortiga Products, Which May Contain Hidden Drug Ingredients
April 20, 2021 --FDA is warning consumers not to purchase or use products marketed with variations of the names “Artri” or “Ortiga” due to potentially dangerous hidden active drug ingredients not list...
FDA Medwatch Alert: Edge Pharma, LLC Issues Voluntary Nationwide Recall of All Drug Products Due to Lack of Sterility Assurance
December 4, 2021 – Colchester, VT, Edge Pharma, LLC is voluntarily recalling all lots of all drugs compounded at Edge Pharma, LLC to the consumer level. All products are being recalled due to process ...
Ocular Therapeutix Announces FDA Approval of sNDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 11, 2021-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
FDA Approves Darzalex (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
HORSHAM, Pa., June 27, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex (daratumumab) in combination w...
Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 21, 2019-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t...
FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for d...
FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous...
Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery
Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care th...
FDA Approves Darzalex (daratumumab) in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, o...
FDA Approves Revised Indication for Ozurdex for the Treatment of Diabetic Macular Edema
IRVINE, Calif.-September 29, 2014 - Allergan, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg, a...
FDA Medwatch Alert: Epidural Corticosteroid Injection: Drug Safety Communication - Risk of Rare But Serious Neurologic Problems
Including methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone [Posted 04/23/2014] ISSUE: FDA is warning that injection of corticosteroids into the epidural space of...
FDA Medwatch Alert: Reumofan Plus: Recall - Undeclared Drug Ingredient
Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol,...
FDA Medwatch Alert: Reumofan Plus Dietary Supplement Relabeled and Sold as “WOW”: Public Warning - Undeclared Drug Ingredients
ISSUE: The U.S. Food and Drug Administration (FDA) is warning the public that the potentially harmful dietary supplement product Reumofan Plus is being relabeled and sold under the name “WOW.” The pr...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Multiple Myeloma, Hay Fever, Allergic Rhinitis, Allergies, Ankylosing Spondylitis, Aphthous Ulcer, Asthma, Asthma - Acute, Contact Dermatitis, view more... Atopic Dermatitis, Bursitis, Eczema, Inflammatory Bowel Disease, Inflammatory Conditions, Juvenile Rheumatoid Arthritis, Leukemia, Systemic Lupus Erythematosus, Lymphoma, Multiple Sclerosis, Nausea / Vomiting, Nausea / Vomiting - Chemotherapy Induced, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Seborrheic Dermatitis, Shock, Transverse Myelitis, Ulcerative Colitis